Kornimate/medical-research-clean huggingface dataset:
lifestyle for the brain health - nutrition and exercise training intervention

Conditions: Aging; Alzheimer Disease; Life Style, Healthy; Exercise; Cognitive Impairment

Summary: due to the increasing incidence of dementia and the lack of causal treatment, non-pharmacological interventions represent an attractive and effective therapeutic strategy of neurodegenerative diseases, such as alzheimer's disease. the aim of the study is to assess the impact of a supervised 9-month intervention with aerobic-strength training and nutritional counseling compared to cognitive training and stretching on the brain, cognitive and motor functions, metabolism, physical fitnes and plasma markers of neurodegenertion in older adults at increased risk of developing alzheimer's disease.


Eligibility criteria:
inclusion criteria: * non-smokers * signed informed consent * presence of subjective or mild cognitive impairment (sci/amci) * elevated levels of selected biomarkers confirming the presence of a pathological process characteristic of alzheimer's disease * absence of any psychological, sociological, or geographical factors that could jeopardize participation in the project. exclusion criteria: * presence of severe cardiovascular, liver, or kidney diseases; advanced or poorly controlled diabetes mellitus (hba1c \>7%), treated with insulin or incretin analogs; cancer or any other severe disease as assessed by the responsible physician. a history of cancer treated with chemotherapy or radiotherapy if within less than 5 years post-treatment. * lack of cooperation, inflexible schedule, or problematic transportation. * insufficient functional capacity or presence of comorbidities that prevent participation in the training program (assessment by an internist, cardiologist, neurologist, orthopedic specialist, or other relevant specialists). * presence of a pacemaker or any metal implants (contraindication for mri examination), or allergy to local anesthetics (contraindication for muscle biopsy). * smoking, alcohol dependence, or addiction to other narcotic substances. * stroke or myocardial infarction within the last year. * long-term treatment for psychiatric disorders - a depressive syndrome is not an exclusion criterion if it is compensated by therapy. * other diseases of the musculoskeletal or nervous system that potentially interfere with the ability to exercise or cognition - such as severe arthritis, parkinson's disease, significant essential tremor, epilepsy, etc. * concurrent participation in another clinical study. * therapy with cholinesterase inhibitors unless the patient is on a stable dose.
effect of adding interferential current to pelvic floor muscle training on vaginismus

Conditions: Vaginismus

Summary: this study aims to determine the effect of adding interferential current to pelvic floor muscle training on vaginismus.

vaginismus is a common sexual problem with a prevalence of 20% in egyptian women, that has a significant impact on a person's life, affecting their physical, emotional, and psychological well-being, as well as their relationships and overall quality of life. there were previous studies that studied the effect of pelvic floor rehabilitation on vaginismus and found that there was a highly significant decrease in pain and pelvic floor muscle spasms, as well as a highly significant increase in sexual function. also, only one previous protocol explored the effect of interferential current on treating vaginismus. but, till now, there is no prior study that investigated the impact of adding interferential current to pelvic floor muscle training on treating vaginismus. this trial has two groups; one will receive interferential current, and the other group will receive interferential current + pelvic floor muscle training

Eligibility criteria:
inclusion criteria: 1. women suffer from primary vaginismus with a duration of marriage ranging from 1 to 12 months. they are diagnosed and referred by the gynecologist. 2. their pain level is ≥ 4 on the visual analogue scale. 3. they have a sedentary lifestyle. exclusion criteria: 1. vaginismus requiring surgical treatment. 2. any gynecological diseases such as pelvic organ prolapse, vulvar vestibulitis, vulvar pain, clitorodynia, vulvar dysesthesia, or any pelvic inflammatory diseases. 3. lower urinary tract infection. 4. husband with sexual dysfunction that prevents penetration. 5. diseases involving nerves and muscles, such as myasthenia gravis. 6. severe psychiatric disorder or cognitive relegation.

Keywords: interferential, pelvic floor training, vaginismus
a study of aripiprazole in patients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (adt) in patients with major depressive disorder who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed antidepressant therapy.


Eligibility criteria:
inclusion criteria: * men and women, 18-65 years old who have experienced single or recurrent, non-psychotic episodes of major depressive disorder, with the current episode of minimally 8 weeks in duration. * treatment history of an inadequate response to at least one and no more than three adequate antidepressant trials.

Keywords: single or recurrent non-psychotic episode of major depressive disorder
assessment of different equations to accurately calculate ldl cholesterol

Conditions: Dyslipidemias; Lipid Disorder

Summary: purpose the ldl-c is a very important marker of the lipid panel which allows the introduction of a treatment and then the follow-up to prevent the cardiovascular risk. friedewald et al have established the most widely used equation at the present time. however, it has many well-known limitations, as being false in postprandial period. new equations have been developed recently. our work consisted in the assessment of the accuracy of friedewald, sampson and martin-hopkins equations and evaluated the consequences in terms of misclassification. given that european recommendations allow the realization of lipid profiles in postprandial period, we studied the accuracy of these equations in non-fasting state . method the ldl cholesterol concentrations will be calculated using at least three different equations (friedewald, sampson, martin-hopkins). results will be compared between equations and between calculated and measured concentrations determined using an ultracentrifugation method. the study is conducted out according to the code of ethics of the world medical association (declaration of helsinki) and obtained the agreement of the scientific and ethics committee of the hospices civils de lyon (ldl equation cnil 21_488) hypothesis to evaluate the most accurate equation in different conditions: * fasting and non-fasting state * in subjects with normal or dyslipidemic lipid profile to evaluate the clinical impact on risk re-classification and lipid treatment goals if ldl-c is calculated using the best equation instead of the friedewald's.


Eligibility criteria:
inclusion criteria: * lipid profile performed in the location 1 during the recruitment period exclusion criteria: * results outside the first and 99th percentile for tg parameters * samples slightly opalescent

Keywords: ldl cholesterol equation postprandial dyslipidemia
phenotype, genotype and biomarkers 2

Conditions: Amyotrophic Lateral Sclerosis; Hereditary Spastic Paraplegia; Primary Lateral Sclerosis; Progressive Muscular Atrophy; Frontotemporal Dementia

Summary: the purpose of this study is to learn more about amyotrophic lateral sclerosis (als) and other related neurodegenerative diseases, including frontotemporal dementia (ftd), primary lateral sclerosis (pls), hereditary spastic paraplegia (hsp), progressive muscular atrophy (pma) and multisystem proteinopathy (msp). more precisely, the investigator wants to identify the links that exist between the disease phenotype (phenotype refers to observable signs and symptoms) and the disease genotype (genotype refers to your genetic information). the investigator also wants to identify biomarkers of als and related diseases.


Eligibility criteria:
inclusion criteria for affected individuals (primary participants) include: * clinical diagnosis or suspicion of als or a related disorder, including, but not limited to, als-ftd, pls, hsp, ftd, multisystem proteinopathy (msp) and pma. * subject is able and willing to comply with study procedures exclusion criteria for affected individuals (primary participants) include: * subjects with a condition or who are in a situation which, in the pi's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol -- including but not limited to neurological, psychological and/or medical conditions inclusion criteria for biological family members (secondary participants) include: * family member of an enrolled affected primary participant exclusion criteria for biological family members (secondary participants) include: * subjects with a condition or who are in a situation which, in the pi's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol -- including but not limited to neurological, psychological and/or medical conditions

Keywords: als pls pma hsp ftd msp
ivf in pediatric concussion

Conditions: Pediatric Mild Traumatic Brain Injury

Summary: children with concussion may improve with intravenous fluids.


Eligibility criteria:
inclusion criteria: * history of acute concussion exclusion criteria: * other significant medical illness
a study of zilovertamab vedotin (mk-2140/vls-101) in participants with solid tumors (mk-2140-002)

Conditions: Triple-negative Breast Cancer; Non-squamous Non-small-cell Lung Cancer; NSCLC; Estrogen-receptor-positive Breast Cancer; Progesterone-receptor-positive Breast Cancer; Estrogen-receptor-negative Breast Cancer; ER-negative Breast Cancer; Progesterone-receptor Negative Breast Cancer; PR-negative Breast Cancer; HER2-negative Breast Cancer; ER-positive Breast Cancer; PR-positive Breast Cancer; Platinum-resistant Ovarian Cancer; Gastric Cancer; Pancreatic Cancer

Summary: this is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (tnbc), non-tnbc human epidermal growth factor receptor 2 (her2)-negative breast cancer, non-squamous non-small-cell lung cancer (nsclc), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. the study will evaluate a null hypothesis that the objective response rate (orr) is ≤5% against the alternative hypothesis that it is ≥20%.

participants enrolled prior to amendment 3 will receive zilovertamab vedotin at 2.5 mg/kg given intravenously on day 1 of repeated 21-day cycles. participants enrolled after amendment 3 will receive zilovertamab vedotin at 1.75 mg/kg given intravenously on day 1 and day 8 of repeated 21-day cycles. treatment will continue until progressive disease or discontinuation.

Eligibility criteria:
inclusion criteria: * has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (tnbc), non-tnbc her2-negative breast cancer, non-squamous non-small-cell lung cancer (nsclc), gastric cancer, pancreatic cancer, or platinum-resistant ovarian cancer. * has metastatic disease that has progressed during or following previous treatment appropriate for the disease type * presence of radiographically measurable disease. * is willing to provide tumor tissue * has adequate organ function * has a negative test or adequate therapy for human immunodeficiency virus (hiv), hepatitis b, and/or hepatitis c. * has completed all prior therapy. * female subjects of childbearing potential must have a negative serum pregnancy test. * both male and female subjects must be willing to use adequate contraception. exclusion criteria: * has peripheral neuropathy of grade \>1. * has a malignancy involving the central nervous system. * has another major cancer. * has an uncontrolled ongoing infection. * has significant cardiovascular disease. * has a known diagnosis of liver cirrhosis. * is pregnant or breastfeeding. * has had major surgery within 4 weeks before the start of study therapy. * has known tumor resistance or intolerance to a prior mmae-containing drug. * is concurrently participating in another therapeutic or imaging clinical trial.
comparison of single vs group embryo culture in micro-well group culture dish

Conditions: Infertility

Summary: does group culture using micro-well group culture dishes improve human blastocyst development compared to single embryo culture?


Eligibility criteria:
inclusion criteria: female age uner 40, male age under 60 patients undergoing ivf-treatment with oocyte collection after ovarian hyperstimulation having signed the study-specific consent form patient fulfilling clinic's standard criteria for blastocyst culture minimum 5 normally fertilized oocytes at the time of fertilization check exclusion criteria: use of any type of surgically retrieved sperm cells patients undergoing any kind of genetic diagnosis at any developmental stage -

Keywords: blastocyst, micro-well group culture dish
genetic basis of rosacea

Conditions: Rosacea

Summary: rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. the exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. the purpose of this study is to develop gene expression profiles of papulopustular rosacea compared to those of normal skin. the investigators hope to better understand the abnormal gene functions that might contribute to this condition. this understanding may lead to the development of additional and better treatments for rosacea.


Eligibility criteria:
eligibility criteria for rosacea group: inclusion criteria for rosacea participants: 1. clinical signs and symptoms of rosacea (papulopustular or erythrotelangiectatic subtypes) present at enrollment as determined by the investigator 2. all four grandparents of european descent 3. fitzpatrick skin type i or ii 4. age 18 years or older exclusion criteria for rosacea participants: 1. unable or unwilling to provide written informed consent 2. concomitant facial or medical condition that obscures diagnosis of rosacea (such as malar erythema from lupus erythematosus) 3. acne vulgaris 4. unable or unwilling to provide peripheral blood sample (a few teaspoons) 5. inability for investigator to verify rosacea diagnosis on clinical examination due to rosacea treatment(s) leading to complete lack of signs and symptoms (such prior laser treatments, systemic tetracycline usage, etc.) 6. use of topical prescription medications or procedures to the face within one month of enrollment 7. women who are pregnant or lactating eligibility criteria for non-rosacea group: inclusion criteria for control participants: 1. no history of rosacea 2. no clinical signs or symptoms of rosacea 3. no family history of rosacea 4. all four grandparents of european descent 5. fitzpatrick skin type i or ii 6. age 18 years or older exclusion criteria for control participants: 1. unable or unwilling to provide written informed consent 2. acne vulgaris 3. unable or unwilling to provide peripheral blood sample (a few teaspoons) 4. women who are pregnant or lactating 5. use of topical prescription medications or procedures to the face within one month of enrollment 6. skin conditions that might interfere with interpretation of procedure results (at the discretion of the investigator)
trial comparing ceftriaxone plus azithromycin versus ceftriaxone for the treatment of gonorrhea

Conditions: Neisseria Gonorrhoeae

Summary: in this randomized controlled trial, the investigators will recruit 42 men attending the sti and hiv clinic at the institute of tropical medicine, with a diagnosis of n. gonorrhoeae and randomize them 1:1 to receive either ceftriaxone or ceftriaxone/azithromycin. they will be followed-up for a test of cure visit at day 14 post-treatment where urine, oropharyngeal and anorectal samples will be taken to test for cure and monitor treatment effects on the microbiome and resistome. the primary outcome will be evaluating the difference in the abundance of resistance conferring genes in the rectal microbiome in the two arms, 14 days after the receipt of therapy.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide written informed consent 2. male sex at birth 3. at least 18 years old 4. confirmed diagnosis of urethritis, proctitis or pharyngitis n. gonnorrhea - symptomatic or asymptomatic (diagnosis of n. gonnorrhea will be by a positive naat performed according to the itms current laboratory protocols or for patients with urethritis a positive gram/methylene blue stain) exclusion criteria: 1. use of any macrolide antibiotics (azithromycin, clarithromycin, erythromycin, roxithromycin, spiramycin) in previous 6 months 2. known contra-indications or allergy to ceftriaxone, azithromycin or lidocaine 3. presence of any other condition, including other sexually transmitted infections that will (likely) require the administration of another antibiotic at the time of enrollment, as assessed by the treating physician
nlp headache speech (nlph-speech): a cross-sectional study on natural language processing analysing spoken monologues by headache patients

Conditions: Headache Disorders

Summary: the research collects spoken descriptions of headache disorders by participants with headache disorders. the speech recordings are analyzed by natural language processing (nlp) tools to analyse linguistic properties of the texts and to obtain insight into the potential of nlp machine learning models for the recognition of headache syndromes of the participants.


Eligibility criteria:
inclusion criteria: * is a patient of the tertiary headache clinic at ghent university hospital * is 18 years or older * has dutch as native speaking language exclusion criteria: * has difficulties in producing spoken language * has limited or no knowledge of dutch
visual outcomes and patient satisfaction with vivity iol in post refractive patients

Conditions: Pseudophakia

Summary: this is a non-interventional, prospective, observational study of the outcomes for post myopic refractive surgery patients following successful, uncomplicated cataract surgery with bilateral implantation of the vivity iol (dat\*\*\*/ccwet\*). patients will be assessed for monocular and binocular distance, intermediate, and near vision.

this is a non-interventional, prospective, single center, bilateral, observational study of the outcomes for 40 post myopic refractive surgery patients following successful, uncomplicated cataract surgery with bilateral implantation of the vivity iol (dat\*\*\*/ccwet\*) performed by 4 surgeons using similar surgical techniques. 40 subjects will be enrolled. patients will be assessed for monocular and binocular distance, intermediate, and near vision. the hypothesis is that post-refractive patients that have high spherical aberration (sas) will have excellent outcomes and satisfaction with a vivity iol

Eligibility criteria:
inclusion criteria: 1. adults, 40 years of age having already undergone cataract removal by phacoemulsification with a clear corneal incision in both eyes with implantation of the vivity iol (dat\*\*\*/ccwet\*) 2. prior uncomplicated, distance-targeted, bilateral myopic lasik or prk (photorefractive keratectomy) surgery and corneal spherical aberration greater than ≥0.30 μ and ≤ 1.20 μ in at least one eye (6.00 mm) as measured at their cataract pre-op visit 3. able to comprehend and willing to sign informed consent and complete all required testing procedures 4. best corrected distance visual acuity (bcdva) projected to be 0.10 logmar (minimum angle of resolution) or better 5. clear intraocular media 6. minimum of two weeks post yag (yttrium aluminum garnet) capsulotomy to treat pco (posterior capsular opacification) 7. residual refractive astigmatism ≤0.50 diopters 8. post-operative refractive spherical equivalent from +0.50 to -0.50 spherical equivalent exclusion criteria: 1. any corneal abnormality, other than regular corneal astigmatism or myopic lasik/prk surgery, (as determined by pre-operative testing) that in the opinion of the investigator would confound the outcome(s) of the study 2. any complication during cataract surgery (capsular tear, vitrectomy, etc) 3. history of or current retinal conditions or predisposition to retinal conditions or predisposition to retinal conditions 4. amblyopia or strabismus in either eye 5. history of or current anterior or posterior segment inflammation of any etiology 6. any form of neovascularization on or within the eye 7. glaucoma (uncontrolled or controlled with medication) 8. optic nerve atrophy 9. subjects with diagnosed degenerative eye disorders 10. postoperative cdva worse than 0.10 logmar in either eye. 11. subjects who have an acute or chronic disease or illness that would confound the results of this investigation in the opinion of the principal investigator (e.g. immunocompromised, connective tissue disease, clinically significant atopic disease, etc)

Keywords: vivity pseudophakia